Tuesday, September 17, 2019

XLRN Pulls The Plug On FSHD Study, KPTI Well Funded, ACRS Up On Wart Trial Data

Today's Daily Dose brings you news about Acceleron Pharma pulling the plug on facioscapulohumeral muscular dystrophy trial; Aclaris Therapeutics' THWART-2 trial results; the $150 million investment by HealthCare Royalty Partners in Karyopharm and the upcoming regulatory catalyst of Seattle Genetics.

from RTT - Biotech https://ift.tt/2UY93nl
via IFTTT

No comments:

Post a Comment